SomaLogic, Inc. Stock Research

Market Summary

USD2.47+0.05

Delayed

2.07%

SLGC Stock Price

SLGC RSI Chart

SLGC Valuation

Market Cap

463.1M

Price/Earnings (Trailing)

-5.57

Price/Sales (Trailing)

6.15

EV/EBITDA

-0.63

Price/Free Cashflow

-4.82

SLGC Price/Sales (Trailing)

SLGC Profitability

EBT Margin

-131.84%

Return on Equity

-13.81%

Return on Assets

-12.09%

Free Cashflow Yield

-20.74%

SLGC Fundamentals

SLGC Revenue

Revenue Y/Y

108.65%

Revenue Q/Q

86.73%

SLGC Earnings

Earnings (TTM)

-83.2M

Earnings Y/Y

20.47%

Earnings Q/Q

-43.32%

Price Action

52 Week Range

2.028.50

(Low)(High)

Last 7 days

-2.8%

Last 30 days

-23.7%

Last 90 days

0.8%

Trailing 12 Months

-68.1%

SLGC Financial Health

Current Ratio

14.56

SLGC Investor Care

Shares Dilution (1Y)

36.68%

Diluted EPS (TTM)

-0.44

Financials for SomaLogic

Income Statement (Last 12 Months)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Revenue	NaN%			-24,096,000	9,260,000	3,649,000
Operating Expenses	16.4%	214,142,000	184,025,000	154,930,000	131,508,000	-
S&GA Expenses	25.9%	148,560,000	117,956,000	95,977,000	77,971,000	58,401,000
R&D Expenses	6.6%	62,047,000	58,224,000	49,178,000	43,496,000	39,873,000
EBITDA	-	-130,706,000	-	-	-	-
EBITDA Margin	-	-1.28	-	-	-	-
Earnings Before Taxes	19.0%	-134,256,000	-165,676,000	-	-	-
EBT Margin	-	-1.32	-	-	-	-
Interest Expenses	-100.0%	0.00	2,000	150,000	1,324,000	10,072,000
Net Income	9.2%	-83,213,000	-91,690,000	-82,042,000	-87,547,000	-73,154,000
Net Income Margin	28.6%	-0.82	-1.14	-0.96	-1.07	-
Free Cahsflow	-28.9%	-96,065,000	-74,528,000	-45,897,000	-43,701,000	-

* denotes actual numbers (not divided by Millions)
Balance Sheet					(In Millions)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Assets	0.3%	688	686	713	706	719
Current Assets	-5.7%	621	659	690	692	707
Cash Equivalents	-9.0%	380	418	438	439	469
Inventory	-10.9%	18.00	21.00	14.00	11.00	11.00
Net PPE	25.6%	20.00	16.00	12.00	10.00	6.00
Goodwill	Infinity%	10.00	-	-	-	-
Liabilities	8.5%	86.00	79.00	96.00	94.00	93.00
Current Liabilities	22.2%	43.00	35.00	28.00	29.00	22.00
Long Term Debt	NaN%	-	-	-	-	-
LT Debt, Current	NaN%	-	-	-	-	-
LT Debt, Non Current	NaN%	-	-	-	-	-
Shareholder's Equity	-0.7%	603	607	617	612	626
Retained Earnings	-6.3%	-558	-525	-502	-498	-475
Additional Paid-In Capital	2.5%	1,162	1,134	1,121	1,111	1,101
Accumulated Depreciation	5.9%	17.00	16.00	16.00	15.00	-
Shares Outstanding	2.2%	187	183	182	182	137

Cashflow (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Cashflow From Operations	-31.3%	-80.47	-61.28	-37.20	-36.97	-23.03
Share Based Compensation	10.9%	43.00	39.00	34.00	28.00	26.00
Cashflow From Investing	91.9%	-8.47	-104	-104	-185	-210
Cashflow From Financing	-99.0%	5.00	541	498	497	677

Risks for SLGC

What is the probability of a big loss on SLGC?

83%

Probability that SomaLogic stock will be more than 20% underwater in next one year

63%

Probability that SomaLogic stock will be more than 30% underwater in next one year.

61%

Probability that SomaLogic stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does SLGC drawdown profile look like?

Y-axis is the maximum loss one would have experienced if SomaLogic was unfortunately bought at previous high price.

Drawdowns

Returns for SLGC

Cumulative Returns on SLGC

Which funds bought or sold SLGC recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-03-10	VICTORY CAPITAL MANAGEMENT INC	added	13.7	-141	36,859	-%
2023-03-07	Madryn Asset Management, LP	added	-	-2,913,000	18,748,000	27.56%
2023-03-06	Rockefeller Capital Management L.P.	added	283	18,000	26,000	-%
2023-03-06	Rockefeller Capital Management L.P.	unchanged	-	-	-	-%
2023-02-28	Voya Investment Management LLC	unchanged	-	-21,748	139,252	-%
2023-02-27	Parallax Volatility Advisers, L.P.	added	29.46	10,037	89,037	-%
2023-02-15	Point72 Middle East FZE	new	-	16,937	16,937	-%
2023-02-15	JANE STREET GROUP, LLC	reduced	-57.71	-67,907	39,093	-%
2023-02-15	Metropolitan Life Insurance Co/NY	unchanged	-	-3,368	23,632	-%
2023-02-15	MetLife Investment Management, LLC	reduced	-19.93	-71,978	163,022	-%

Latest Funds Activity

Are funds buying SLGC calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own SLGC

No. of Funds

SomaLogic News

Schedule 13G FIlings of SomaLogic

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2023	gold lawrence marshall	1.9%	3,627,197	SC 13G/A
Feb 03, 2023	blackrock inc.	5.5%	10,268,281	SC 13G
Dec 14, 2022	cmls holdings ii llc	5.8%	11,146,669	SC 13D/A
Feb 11, 2022	gold lawrence marshall	5.04%	9,133,066	SC 13G

SLGC Fair Value

Recent SEC filings of SomaLogic

View All Filings

Date Filed	Form Type	Document
Mar 09, 2023	8-K	Current Report
Feb 17, 2023	8-K	Current Report
Feb 14, 2023	SC 13G/A	Major Ownership Report
Feb 14, 2023	8-K	Current Report
Feb 03, 2023	SC 13G	Major Ownership Report
Jan 10, 2023	8-K	Current Report
Jan 09, 2023	8-K	Current Report
Dec 14, 2022	SC 13D/A	13D - Major Acquisition
Dec 14, 2022	4	Insider Trading

Latest Insider Trading transactions for SLGC

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2022-09-29	Casdin Eli	acquired	-	-	215,193	-
2022-09-13	Blakeman Shaun M.	acquired	-	-	200,294	chief financial officer
2022-09-13	Graves Amy	acquired	-	-	60,011	chief accounting officer
2022-09-13	Smythe Roy	acquired	-	-	91,968	chief executive officer
2022-09-13	Gutierrez Ruben	acquired	-	-	85,510	general counsel
2022-04-07	POST RICHARD A	acquired	190,912	4.7728	40,000	-
2022-03-01	Harris Melody	acquired	-	-	48,125	president and coo
2022-03-01	Gutierrez Ruben	acquired	-	-	10,000	general counsel
2022-03-01	Smythe Roy	acquired	-	-	72,500	chief executive officer
2022-03-01	Graves Amy	acquired	-	-	12,500	chief accounting officer

About SomaLogic

Roy Smythe

https://somalogic.com/

320

SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various types of biological samples for protein biomarker signatures, which can be utilized in drug discovery and development. Its SomaScan's biomarker discoveries help in diagnostic applications in various areas of diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company also provides SomaSignal research use only and laboratory-developed tests. It serves research and clinical customers with a focus on pharmaceutical and biotechnology companies, and academic research institutions, as well as facilitates drug development, analysis of clinical trials, and new human biology insights by assessing protein-protein and protein-gene networks. The company was incorporated in 1999 and is headquartered in Boulder, Colorado.

SLGC Income Statement

2022-09-30

Condensed Consolidated Statements of Operations and Comprehensive Loss Unaudited - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenue
Collaboration revenue	$ 763	$ 763	$ 2,288	$ 2,288
Other revenue	22,325	1,655	27,026	7,306
Total revenue	41,713	19,992	78,837	58,632
Operating expenses
Research and development	19,419	15,596	50,855	32,304
Selling, general and administrative	51,236	20,632	118,863	48,274
Total operating expenses	82,325	44,998	200,117	103,578
Loss from operations	(40,612)	(25,006)	(121,280)	(44,946)
Other income (expense)
Interest income and other, net	2,417	55	3,456	126
Interest expense	0	(2)	0	(1,324)
Change in fair value of warrant liabilities	3,371	(8,111)	30,547	(8,111)
Change in fair value of earn-out liability	1,260	(5,662)	26,749	(5,662)
Loss on extinguishment of debt, net	0	(2,693)	0	(4,323)
Total other income (expense)	7,048	(16,413)	60,752	(19,294)
Net loss before income tax benefit	(33,564)	(41,419)	(60,528)	(64,240)
Income tax benefit	622	0	622	0
Net loss	(32,942)	(41,419)	(59,906)	(64,240)
Other comprehensive loss
Net unrealized loss on available-for-sale securities	(13)	(15)	(874)	(7)
Foreign currency translation loss	(14)	(4)	(28)	(3)
Total other comprehensive loss	(27)	(19)	(902)	(10)
Comprehensive loss	$ (32,969)	$ (41,438)	$ (60,808)	$ (64,250)
Net loss per share, basic (in usd per share)	$ (0.18)	$ (0.30)	$ (0.33)	$ (0.53)
Net loss per share, diluted (in usd per share)	$ (0.18)	$ (0.30)	$ (0.33)	$ (0.53)
Weighted-average shares outstanding, basic (in shares)	184,407,874	137,176,228	183,209,213	122,268,443
Weighted-average shares outstanding, diluted (in shares)	184,407,874	137,176,228	183,209,213	122,268,443
Assay services revenue
Revenue
Revenue	$ 17,574	$ 17,499	$ 47,305	$ 48,308
Operating expenses
Cost of revenue	11,264	8,737	29,215	22,548
Product revenue
Revenue
Revenue	1,051	75	2,218	730
Operating expenses
Cost of revenue	$ 406	$ 33	$ 1,184	$ 452

SLGC Balance Sheet

2022-09-30

Condensed Consolidated Balance Sheets Unaudited - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets
Cash and cash equivalents	$ 380,374	$ 439,488
Investments	185,963	218,218
Accounts receivable, net	25,050	17,074
Inventory	18,499	11,213
Deferred costs of services	1,217	462
Prepaid expenses and other current assets	10,157	5,097
Total current assets	621,260	691,552
Non-current inventory	3,810	4,085
Accounts receivable, net of current portion	10,383	0
Property and equipment, net of accumulated depreciation of $17,416 and $15,244 as of September 30, 2022 and December 31, 2021, respectively	19,910	9,557
Other long-term assets	5,716	908
Intangible assets	16,700	0
Goodwill	10,465	0
Total assets	688,244	706,102
Current liabilities
Accounts payable	20,295	15,089
Accrued liabilities	16,324	11,109
Deferred revenue	3,611	3,021
Other current liabilities	2,445	66
Total current liabilities	42,675	29,285
Warrant liabilities	4,635	35,181
Earn-out liability	136	26,885
Deferred revenue, net of current portion	32,015	2,364
Other long-term liabilities	6,113	363
Total liabilities	85,574	94,078
Commitments and contingencies (Note 9)
Stockholders’ equity
Preferred stock, $0.0001 par value; 1,000,000 shares authorized; no shares issued and outstanding at September 30, 2022 and December 31, 2021	0	0
Common stock, $0.0001 par value; 600,000,000 shares authorized; 187,495,940 and 181,552,241 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively	19	18
Additional paid-in capital	1,162,444	1,110,991
Accumulated other comprehensive loss	(974)	(72)
Accumulated deficit	(558,819)	(498,913)
Total stockholders’ equity	602,670	612,024
Total liabilities and stockholders’ equity	$ 688,244	$ 706,102